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Abstract
Background—The collection of induced
sputum provides a non-invasivemethod of
investigating airway inflammation. Few
studies have been performed in children,
so a study was undertaken to determine
the feasibility of sputum induction, the
repeatability of eosinophil counts and
sputum eosinophil cationic protein (ECP)
levels, and the relation of these to current
asthma severity. For comparison, serum
ECP levels were also measured.
Methods—In a cross sectional study of
children aged 5–15 years, 27 healthy
children and 60 with asthma underwent
sputum induction using inhaled nebulised
hypertonic saline. The whole sputum
sample was used for analysis. Ten children
with stable asthma repeated the proce-
dure within 10 days.
Results—A satisfactory sample (>500
non-squamous cells) was obtained in 61%
of children with asthma and in 60% of
healthy controls. The limits of agreement
within subjects ranged from a 0.68 to 2.8
fold diVerence for eosinophil diVerential
counts and from 0.38 to 4.4 fold for
sputum ECP. Despite a median of 42%
squamous cells, significant diVerences
were found between asthma and healthy
controls for the eosinophil diVerential
count (p = 0.0004), total eosinophil counts
(p = 0.03), and sputum ECP level (p =
0.0001). Overall, there was no correlation
between any marker of airway inflamma-
tion and asthma severity, however ex-
pressed, including lung function.
Conclusions—Sputum induction is only
possible in a proportion of children. The
repeatability of sputum cell counts and
ECP levels, measured in a small number
of children, was similar to that reported in
adults. Sputum analysis revealed no evi-
dence of airway inflammation in a
number of highly symptomatic children
with asthma.
(Thorax 2000;55:768–774)
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Asthma in both adults and children is associ-
ated with airway inflammation.1 2 Inhaled
corticosteroids are widely used to treat airway
inflammation in asthma, but the relation
between the dose needed to control symptoms,
reduce inflammation or, in the long term, to
prevent airway remodelling is not known.
Treatment is mostly on an empirical basis and
it is rarely known whether or not the optimum
anti-inflammatory eVect has been achieved.
Evidence of airway inflammation can be found
even in those with mild or well controlled
symptoms.3 There is an obvious need for a
non-invasive means of assessing airway inflam-
mation, particularly in children in whom direct
methods of assessment are rarely possible.
The assessment of induced sputum can pro-
vide a useful tool for monitoring airway
inflammation.3 4 Airway inflammation, re-
flected by an increase in the eosinophil
diVerential cell count, eosinophil cationic pro-
tein (ECP), and inflammatory cytokines, has
been demonstrated in sputum induced by
inhalation of hypertonic saline.4 There is
limited information concerning the use of
induced sputum in children,5–7 although con-
siderable numbers of studies have confirmed
the reliability of the method in adults and have
shown a reduction in inflammation following
treatment with inhaled corticosteroids (ICS).1 8
The purpose of this study was threefold.
Firstly, to assess the feasibility of inducing spu-
tum in children. For the result of a test to have
general application it must be possible for it to
be performed by the majority of the subjects
attempting it, without bias in the diVerent
groups being studied. Secondly, we were inter-
ested in the repeatability of this method in chil-
dren. This was assessed for eosinophils, both
within a single sample by one observer and
between two observers, and also for cell counts
and sputum ECP levels within subjects with
stable asthma by repeating the test twice within
10 days. Our third objective was to investigate
the relation between evidence of airway inflam-
mation and the level of current symptoms in
children who were treated with a wide range of
inhaled corticosteroids (none, low dose, high
dose). To do this a daily asthma record was
kept of symptoms, bronchodilator use, and
twice daily peak expiratory flow rates for two
weeks before sputum was induced. For com-
parison, sputum was also induced in healthy
control children of a similar age. Since several
groups have advocated the use of serum ECP
as an indirect marker of airway inflammation,
this was also measured.9 10
Methods
SUBJECTS
Children with asthma were recruited from the
Paediatric Asthma Clinic of the Hammersmith
Hospital if they were either currently sympto-
matic despite treatment with ICS or they were
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not being treated with ICS but had experi-
enced symptoms in the preceding three
months. In the latter category, some children
with episodic symptoms were included. No
child was taking any other anti-inflammatory
agent. All had typical asthma with documented
variable bronchoconstriction and no other
diagnosis.
Healthy controls were recruited from sib-
lings of children attending one of the paediatric
clinics (including the asthma clinic) or from
children of staV. A parent was interviewed and
a paediatrician examined the child to confirm
the lack of past or present lower respiratory
disease. Atopic children were not excluded.
Any child of seven years or older was
approached if they fulfilled these criteria. In
addition, three children aged less than six years
were recruited as they were, unusually for their
age, able to perform reproducible spirometric
tests.
No child was tested within two weeks of a
clinical viral infection.
STUDY PROTOCOL
Children with asthma kept an asthma diary in
which symptoms, bronchodilator usage, and
twice daily peak flow (PEF) were recorded for
two weeks immediately before attending the
paediatric asthma laboratory for (a) spiromet-
ric tests (Vitalograph, Compact, Buckingham,
UK), (b) hypertonic saline inhalation and spu-
tum induction (if the forced expiratory volume
in one second (FEV1) was >70% predicted),
(c) skin prick tests to five common allergens
(house dust mite, cat, dog, grass and feathers,
Pharmacia, Uppsala, Sweden), and (d)
venepuncture for eosinophil count and
measurement of total IgE and ECP levels
(RIA, Pharmacia) after application of local
anaesthetic cream.
Healthy control children underwent spiro-
metric tests, hypertonic saline inhalation,
sputum induction, and skin prick tests but did
not have blood taken.
REPEATABILITY
The between observer repeatability was calculated
by comparing the diVerential cell counts
between the two independent observers count-
ing the same slides, blind to each others’
results. Both asthma and control samples were
used.
To obtain the within subject repeatability, 10
asthmatic subjects with stable asthma were
asked to return within 10 days to undergo the
identical protocol. The repeat counts were
made blind to the initial findings. Only subjects
with no change in medication or symptom
severity were included.
The within sample repeatability was deter-
mined by comparing the results of one observer
from the original set of slides with the results
from a diVerent set of slides obtained from the
same sputum sample, counted independently
under blind conditions, by the same observer,
from 15 individuals selected at random from
the asthma samples.
ASSESSMENT OF ASTHMA SEVERITY
The functional residual severity was defined as
the level of symptoms irrespective of
treatment.11 The percentage of symptom free
days and the percentage of disturbed nights
and days with exercise induced symptoms were
noted from the records of the asthma diary
kept for two weeks before the investigation.
The severity of the asthma was also assessed
according to the current treatment: (i) no ICS
(non-ICS); (ii) ICS low dose (up to 400 µg/
day); (iii) ICS high dose (>400 µg/day).
SPUTUM INDUCTION
Hypertonic saline (4.5%) was inhaled through
a mouth piece and a large two-way valve (Hans
Rudolph Inc, Kansas, USA) connected to a
Timeter nebuliser (Oregon, Pike, Pennsylva-
nia, USA) set at maximum output (at least
2 ml/min). Inhalations were carried out for
doubling periods of time, starting at two
minutes and continued up to a maximum
period of 16 minutes. After each inhalation
period the child was asked to cough and expec-
torate into the provided pot. The FEV1 was
measured after each inhalation to screen for
bronchoconstriction. The inhalations were
repeated up to a cumulative total time of 30
minutes, or until a sputum sample was
obtained. If there was no sample by then, neb-
ulised salbutamol (2.5 mg) was given to
prevent bronchoconstriction. The hypertonic
saline inhalations were then resumed for a fur-
ther period of 15 minutes without the valve to
increase the inhaled dose of aerosol in a further
attempt to induce a sample.
SAMPLE PROCESSING
The sputum and saliva samples were processed
within half an hour of production. Sputum
samples were considered satisfactory if at least
500 non-squamous cells could be counted.
The entire sputum volume was measured
and an equal volume of dithiothreitol 0.1%
(DTT, Sputolysin; Calbiochem Corporation,
San Diego, California, USA) was then added
and the whole sample was mixed at 37°C for 20
minutes to ensure homogenisation. The sam-
ple was centrifuged at 1000g for 10 minutes
and aliquots of the supernatant were taken and
stored at –70°C for a later biochemical analysis.
The pellet was resuspended in a volume of
phosphate buVered saline (PBS) equal to the
previous volume of DTT to obtain a total cell
count in a Neubauer haemocytometer. Cell
viability was assessed by the trypan blue exclu-
sion method, the blue cells being considered
dead. The cell suspension was then adjusted to
1.0 × 106 cells/ml and 100 µl of cell suspension
were placed into the cups of a Shandon 11
cytocentrifuge (Shandon, Southern Instru-
ments, Sewickley Park, Pennsylvania, USA).
The cytospins were prepared at 450g for six
minutes. The slides were air dried and stained
with May-Grunwald-Giemsa stain. The mean
of 500 non-squamous cells, counted by two
independent observers, was used to obtain the
diVerential cell count.
Sputum supernatant was analysed in batches
for ECP (RIA, Pharmacia). The upper limit of
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measurement was 200 µg/l. This was expressed
as concentration/ml of undiluted supernatant
(upper limit of detection 400 µg/l).
Blood samples, collected into plain glass,
were allowed to clot at room temperature for
one hour and were then centrifuged for 10
minutes at 1000g before the serum was
removed, frozen at –20°C, and stored for later
analysis of serum ECP levels, total IgE, and
house dust mite specific IgE (RAST).
The project was approved by the Hammer-
smith Hospital ethics committee and informed
written consent was obtained from a parent
and also the child if appropriate.
STATISTICAL ANALYSIS
Minitab software (Release 12, State College,
USA) was used to perform statistical analysis.
For diVerential and total cell counts the data
are presented as medians and interquartile
range (IQR). Because of markedly skewed data
distribution in cell counts, the Kruskal-Wallis
ANOVA was used to make comparisons. Com-
parisons of cell counts between groups were
made with a Mann-Whitney test, with an
adjustment for multiple comparisons. Both
tests adjusted for tied values. DiVerences in
sputum and serum ECP concentrations be-
tween groups were compared using the Stu-
dent’s t test after log transformation. Correla-
tions between variables were made using
Spearman’s rank correlation.
To demonstrate the limits of agreement of
repeated values of eosinophil diVerential
counts, eosinophil numbers, and total cell
counts Bland and Altman plots were
constructed.12 In order to overcome the prob-
lem of the relation between the SD of the
diVerence and its mean value, the mean values
were plotted against the ratio of the two values
rather than the diVerences. Because of the
small numbers, the range of the ratios of repeat
values is given. The intraclass correlation coef-
ficient (or coeYcient of reliability, R) was
calculated (i) using the SD of the ratios for
eosinophil diVerential count and number, and
the total cell counts; and (ii) the SD of
diVerences for log ECP to determine the
proportion of the variances between the
compared pairs to the total variance. In
addition, the geometric coeYcient of variation
was calculated for the non-normally distrib-
uted variables and the coeYcient of variation
for log ECP.13
Results
FEASIBILITY OF SPUTUM SAMPLE PRODUCTION
Eight children of median (range) age 7 (5–13)
years were unable to cooperate with the
sputum induction protocol; 34 of the remain-
ing 87 (39%) were unable to produce a
satisfactory sputum sample (defined as con-
taining at least 500 non-squamous cells), the
majority having a dry cough only (table 1).
There was no age diVerence between those
who produced a sample (median 10.1 years
(range 5–15)) and those who did not (median
9.6 years (range 5–15)). As only two children
under seven years were invited to take part on
the grounds that they could expectorate to
order and were exceptionally good at perform-
ing spirometric tests for their age, feasibility in
the younger age was not fairly assessed. There
was no diVerence in age, asthma severity, or
treatment category between those who did and
those who did not produce a sputum sample.
There was no diVerence in the proportion of
children able to produce a sample between the
asthma and control groups (36/60 (60%)
versus 17/27 (61%), table 1).
Of the 36 children with asthma from whom
a sputum sample was obtained, 15 were treated
with ICS (seven low dose and eight high dose)
and 21 were treated with bronchodilators only
(non-ICS); four of the ICS group were also
taking a long acting bronchodilator. Symptom
severity in the preceding two weeks in the two
groups is shown in table 2. Five of the 43 spu-
tum samples were obtained only after the
removal of the Hans Rudolph valve (leading to
a prolonged inhalation period and increased
lung dose of hypertonic saline).
Cell viability ranged between 50% and 89%
with no significant diVerence between asth-
matic and control children (median values
70% and 67%, respectively).
SQUAMOUS CELL CONTAMINATION
Squamous cell contamination was high, the
median proportion of squamous cells being
42% (IQR 26–50%). The proportion of
squamous cells was unrelated to the eosinophil
count or the level of ECP in the supernatant.
There was no diVerence between asthmatic
and healthy children (p = 0.66).
REPEATABILITY
Within sample and within observer
The relation between values for eosinophil dif-
ferential counts in both comparisons was best
when counts were high but discrepancies were
seen between observers and within samples
with low counts (table 3).
Table 1 Feasibility of sputum sample production and comparison of cellular morphology and sputum ECP between asthma and healthy controls
No. of
subjects Age (years)
Mean (SD)
FEV1 (%)
Skin prick test
positive (%)
Sample
production† (n) (%)
Eosinophils
(×106/ml) (%)
Total cell count
(×106/ml)
ECP
(µg/l)
Control 27 9.8 (8.4–11.9) 91 (12) 38 17 61 0 (0–0) 0 (0–0) 2.4 (0.9–2.8) 8.8 (2–25)*
Asthma 60 10.2 (8.4–11) 91 (21) 62 36 60 0.04 (0–0.4) 0.02 (0–1.3) 2.4 (1.7–4.3) 83 (34–258)*
p value 0.59 0.9 0.02 0.03 0.004 0.34 <0.001
Values as median (IQR) except *geometric mean. †Eight other children were unable to cooperate with the technique.
Table 2 Symptom severity in preceding two weeks in children with asthma, with and
without treatment with inhaled corticosteroids (ICS)
No. of
subjects FEV1 (%)
Symptomatic days
(%)
Nocturnal
symptoms (%) EIA (%)
No ICS 21 93 (13) 33 (15–80) 14 (0–33) 15 (0–32)
ICS 15 89 (25) 63 (29–100) 25 (0–65) 36 (18–78)
p value 0.98 0.07 0.53 0.04
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Within subject
The overall within subject repeatability (R) was
satisfactory for eosinophil diVerential counts
and total counts as well as for ECP levels but
was less so for the total cell count (table 3). The
limits of agreement for repeat eosinophil
diVerential counts ranged from 0.68 to 2.4 fold
(mean 1.15), for eosinophil number the range
was 0.7–4.55 fold (mean 1.6), for the total cell
count it was 0.7–4.55 fold (mean 1.16), and for
ECP levels the range was 0.38–4.4 fold (mean
1.54) (fig 1).
COMPARISON BETWEEN ASTHMATIC CHILDREN
AND CONTROLS
There was a significantly higher eosinophil dif-
ferential count in the sputum of children with
asthma than in the controls (95% confidence
interval of diVerence (CI) 0.002 to 0.84; p =
0.004) and the sputum ECP level was
significantly higher (95% CI 0.035 to 0.21;
p<0.0001, table 1). The proportion of sputum
eosinophils was not increased in the asthma
ICS group compared with controls (p = 0.68)
but the ECP concentration was significantly
higher (p = 0.004, fig 2). In the non-ICS group
of patients both the proportion of eosinophils
(p = 0.0002) and the ECP levels (p<0.0001)
were significantly higher than in controls (fig
2). There was a significant correlation in the
sputum between the percentage of eosinophils
and ECP levels (r2 = 0.28, p<0.001). There was
also a weak correlation between sputum and
serum levels of ECP (r2 = 0.17, p = 0.03).
EOSINOPHILS, ECP LEVELS, AND ASTHMA SEVERITY
The study had the ability to detect a correlation
of at least 0.45 (Spearman’s rank correlation
coeYcient) with 80% power at the 5% level
between sputum eosinophils and indices of
asthma severity. For all the children with
asthma (ICS and non-ICS) there was no
relationship between any currently measured
index of asthma severity, including lung
function, and the percentage of eosinophils or
sputum or serum levels of ECP (fig 3). There
was no diVerence in FEV1 between those with
any eosinophils and those with none (mean
(SD) FEV1 90 (12)% predicted versus 93
(25)% predicted; p = 0.72). Similarly, in
children with asthma with increased values of
ECP in either blood or sputum (judged by
levels above either the upper quartile for
asthma or the maximum values found in
healthy children) there was no diVerence in
FEV1 compared with those with normal ECP
levels.
When the sputum and serum results were
considered for the ICS and non-ICS groups
separately, or when the ICS group was divided
into high dose (n = 8) and low dose (n = 7)
subgroups, there was still no relation with any
Table 3 Repeatability: intraclass correlation coeYcients and geometric coeYcients of
variation
Eosinophil
diVerential count
Eosinophil total
count
Total cell
count ECP
Intraclass correlation coeYcient (R)
within subject (between days) 0.93 0.90 0.63 0.92
between observer (two observers) 0.98 – – –
within sample (two preparations) 0.82 – – –
Geometric coeYcient of variation
(%) within sample
29 43 79 65
Figure 1 Range of agreement for repeat values performed twice in the same subject within 10 days for (A) eosinophil
diVerential count (%), (B) eosinophil number (106/ml), (C) total cell counts (106/ml), and (D) ECP (µg/l) in sputum
supernatant.
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clinical index of current symptom severity, nor
was there any relation between evidence of
inflammation and medication category (non-
ICS, high or low dose ICS).
Discussion
Using this technique of sputum induction we
have shown significant diVerences in the
proportion of eosinophils and in sputum ECP
levels between children with asthma and
healthy children and some diVerences between
those treated with ICS and those who were not.
Fifty six percent of the children tested were
able to produce a satisfactory sample. This
included the small number who were unable or
refused to cooperate with the protocol. This is
much lower than the 92% success rate reported
in a recent Australian epidemiological study7
and could be due to diVerences in the sputum
induction method or in the criteria used to
define a satisfactory sample.
Repeatability was considered in several ways.
In the 10 children tested on two occasions no
eosinophils were found in five on both
occasions; unfortunately, only one child with
very high levels was studied twice, but he
showed a repeatable result. The repeatability
was less good with low eosinophil levels, but
this not likely to be of clinical significance
where levels are within the normal range. Simi-
larly, marked variation between observers was
only seen at low eosinophil levels. Estimations
of the limits of agreement and the geometric
coeYcient of variation of the eosinophil diVer-
ential counts were also aVected by the
unreliability of low eosinophil values. When
diVerent slides made from a single sample were
compared blind by one observer the variation
in values was small, indicating that the
measurement was representative of the whole
sample. The intraclass correlation coeYcient,
which considers the contribution of the vari-
ance between measurements to the total
variance, was highly acceptable in this study for
sputum eosinophils and ECP levels both within
subjects and between observers. Our findings,
in the small numbers of repeat measurements
made, were similar to those previously reported
in adults.4 14 15 However, the intraclass correla-
tion coeYcient is highly sensitive to subject
selection and is improved by a wide variation in
values between subjects, as was found in our
asthmatic group. The eosinophil diVerential
count showed a better repeatability than the
total count, as has been reported previously,16
probably as the result of salivary contamination
leading to variable sputum dilution. This is
reflected in the increased coeYcients of
variation and range of agreement for total cell
count and sputum ECP levels.
Considering the two asthma treatment
groups separately, the asthmatic children not
treated with ICS diVered from controls in both
eosinophil diVerential count and sputum ECP
levels; in the ICS group the sputum ECP level
was higher than in healthy children but there
was no diVerence in eosinophil diVerential
count. The lack of diVerence between controls
and children treated with ICS is unlikely to be
due to the small numbers in the group as eosi-
nophils were found in only a few ICS treated
children, in many of whom sputum levels of
Figure 2 (A) Sputum eosinophil diVerential count: control versus asthma non-ICS, p = 0.003; asthma non-ICS versus
asthma ICS, p = 0.02; control versus asthma ICS, not significant. (B) Sputum ECP levels in the three groups of subjects:
control versus asthma non-ICS, p = 0.004; control versus asthma ICS, p<0.001; asthma ICS versus asthma non-ICS, not
significant. Diamonds represent individuals with occasional (episodic) symptoms only.
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ECP were increased (fig 2). A similar discrep-
ancy between the two has also been previously
noted in adults17 and one possible explanation
for this finding is the eVect of DTT in dispers-
ing cells, which has been shown to increase
sputum levels of ECP but not to alter the cell
count.18 However, this should aVect both treat-
ment groups similarly.
As we used the “whole sample” method of
sputum analysis, a high proportion of
squamous cells was present from inevitable
salivary contamination. This is one possible
explanation for the lack of eosinophils in
symptomatic children with asthma treated with
ICS.19 However, squamous cell contamination
did not diVer between ICS and non-ICS
children, and is therefore unlikely to have
masked real diVerences in cell counts.
The results of induced sputum analysis in
asthmatic children have been reported in a few
studies.3 5 7 20 In most cases selected sputum
portions, rather than the whole sample, were
used. The diVerences in eosinophil diVerential
counts between asthmatic and healthy controls
were similar to the present study. Considera-
tion of sputum indices and asthma severity has
infrequently been reported in children, but a
lack of a relationship was also noted in a popu-
lation study.7 In another study eosinophils were
significantly increased in those with poor con-
trol compared with those with good asthmatic
control.3 The diVerence could either be due to
the fact that children with a recent acute exac-
erbation were included or poor compliance
with treatment led to both poor control and
high eosinophil levels. In our study we
excluded children who had recently been
treated with oral corticosteroids and those with
a recent virus infection, the most usual cause of
acute exacerbations.21 In children with an acute
exacerbation of asthma very high levels of both
eosinophils and neutrophils were found in the
sputum, but these soon fell on recovery.6
Early studies of serum ECP levels in asthma
recommended its measurement as a clinical
tool for monitoring airway inflammation.9 22
However, the relation of serum ECP levels to
asthma severity is controversial.23 Our results
are in accordance with others in showing a
poor relationship between serum ECP levels
and symptom severity.23 24 Indeed, we used
three markers of airway inflammation but none
of them related to current asthma symptoms,
which was disappointing. In studies in adults
the relation between airway eosinophils and
asthma severity is also unclear.14 25 On the other
hand, most studies in adults and one in adoles-
cents with severe asthma have found a correla-
tion between lung function and inflammatory
indices.16 26–28 In contrast, as was the case for
Piacentini and colleagues who studied children
with mild to moderate asthma, in our study
there was none.20 This could be because airway
remodelling is related to chronic airway
inflammation and occurs only after a pro-
longed period of time, so it may not be
established in children. Some children with
asthma that is diYcult to control have surpris-
ingly good lung function. For example, in the
present study 67% of the children had an FEV1
of >80% predicted, despite a mean of only nine
asymptomatic days in the preceding two weeks.
There is still much to be learnt about the
relationship between measures of inflamma-
tion, severity of asthma, and the response to
anti-inflammatory treatment. The precise rela-
tionship may depend on the individual. In our
group of non-ICS children we found some with
very high eosinophil counts but minimal
asthma symptoms (fig 3); it would be interest-
ing to know whether this finding represents a
risk factor which predicts severe symptoms. In
ICS treated children high values may be a
marker of treatment non-compliance. In con-
trast, some highly symptomatic children
treated with high-dose ICS were without any
evidence of airway eosinophil activity (fig 3). It
is not clear whether this is due to diYculty in
assessing asthma severity or because the
relationship between airway inflammation and
asthma symptoms has too many dimensions to
be detected in such a simple assessment.27 The
latter seems the most likely, as no relation
between severity and inflammatory cells was
seen when the more direct methods of
bronchoalveolar lavage and bronchial biopsy
were used.25 27 Another possibility is that the
persistence of asthma symptoms despite high
dose anti-inflammatory treatment results from
a factor that is independent of eosinophilic
inflammation such as autonomic dysfunction.
We conclude that, of those able to cooperate
with the sputum induction process, about two
thirds will produce a sample that can be
analysed. Since there was no diVerence in the
ability to produce a sample between healthy
children and asthmatics, with or without ICS
treatment, or between children with diVerent
severity of asthma, this low feasibility rate is
unlikely to invalidate studies of airway pathol-
ogy in asthma. However, it has important
implications for the workload entailed in
research projects. Although we used a method
in which there were high levels of salivary and
squamous cell contamination, we were able to
distinguish between asthmatic and control
children, not only by total and diVerential
eosinophil counts but also by the ECP levels in
the supernatant. Sputum ECP levels but not
eosinophil numbers were increased in ICS
treated asthmatics with a high level of current
symptoms. None of the three inflammatory
markers studied (sputum eosinophils, sputum
ECP, and serum ECP) was related to current
symptom severity or lung function. We were
unable to detect any evidence of eosinophilic
airway inflammation in several children with
persisting asthma. In these children it is not
clear whether or not an increase in their anti-
inflammatory treatment is indicated. On the
other hand, those with clear evidence of airway
inflammation require an increase in, or better
supervision of, anti-inflammatory treatment.
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